Although little is known about the regulatory mechanism of CD30 surface expression in CTCL, constitutive signaling via JAK/STAT might indeed confer one possible method to upregulate CD30 expression in MF due to STAT-responsive elements within the CD30 promotor [56]. The gene discussed is TNFRSF8; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.